Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Oncolytics Biotech Inc (TSX: ONC )

3.620 CAD +0.020 (+0.56%)
Streaming Delayed Price Updated: 3:59 PM EST, Jan 20, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Oncolytics Biotech Inc

< Previous 1 2 3 4 5 6 Next >
Pelareorep Along With Checkpoint Inhibitors Proving Critically Important for Early Stage Breast Cancer
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Pelareorep Along With Checkpoint Inhibitors Proving Critically Important for Early Stage Breast Cancer
Financialnewsmedia.com News Commentary 
From PR Newswire
Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint Inhibitors at the 2020 San Antonio Breast Cancer Symposium
Tags ONCY News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint Inhibitors at the 2020 San Antonio Breast Cancer Symposium
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) and SOLTI-Innovative Breast Cancer Research today published an electronic poster at the 2020 San Antonio Breast Cancer Symposium (SABCS) with data... 
From PR Newswire
Thinking about buying stock in Pfizer, Nio, Lexicon Pharmaceuticals, Oncolytics Biotech, or Boeing?
InvestorsObserver issues critical PriceWatch Alerts for PFE, NIO, LXRX, ONCY, and BA. 
From PR Newswire
Thinking about buying stock in Oncolytics Biotech, Virgin Galactic, American Airlines, Norwegian Cruise Line, or Intel Corp?
InvestorsObserver issues critical PriceWatch Alerts for ONCY, SPCE, AAL, NCLH, and INTC. 
From PR Newswire
New Pharma Trials Making Big Gains in Fight Against Triple-Negative Breast Cancer (TNBC)
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
New Pharma Trials Making Big Gains in Fight Against Triple-Negative Breast Cancer (TNBC)
FN Media Group Presents USA News Group News Commentary 
From PR Newswire
Oncolytics Biotech® Announces Positive Clinical Results Against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting
Pelareorep delivers efficacy, safety, and tolerability in difficult-to-treat GBM 
From PR Newswire
Oncolytics Biotech® to Present AWARE-1 Data and Provide Updates on Phase 2 BRACELET-1 and IRENE Trials at the 2020 San Antonio Breast Cancer Symposium
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of three abstracts for electronic poster presentations to be given as part of the 2020 San Antonio Breast Cancer... 
From PR Newswire
Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results
Recently announced AWARE-1 data further support the potential of pelareorep to induce a durable anti-tumor immune memory effect and improve outcomes in breast cancer 
From PR Newswire
Biotech Brief: Breast Cancer Drug Market Could Exceed $38 Billion By 2025
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Biotech Brief: Breast Cancer Drug Market Could Exceed $38 Billion By 2025
Financialnewsmedia.com News Commentary 
From PR Newswire
Oncolytics Biotech® and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at The Society for Immunotherapy of Cancer Annual Meeting
Tags ONCY News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Oncolytics Biotech® and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at The Society for Immunotherapy of Cancer Annual Meeting
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) and SOLTI-Innovative Breast Cancer Research today announced the publication of an electronic poster with clinical data from the AWARE-1... 
From PR Newswire
Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting
- Data from a phase 1b, investigator-sponsored study show that a pelareorep-based combination therapy is safe and well-tolerated in newly diagnosed glioblastoma multiforme patients 
From PR Newswire
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Wednesday, November 11, 2020, at 5:00 pm ET to discuss a corporate update and... 
From PR Newswire
Thinking about buying stock in Scholar Rock Holding, Electrameccanica Vehicles, Verastem, Oncolytics Biotech, or Cisco Systems?
InvestorsObserver issues critical PriceWatch Alerts for SRRK, SOLO, VSTM, ONCY, and CSCO. 
From PR Newswire
Thinking about buying stock in Tilray, Delta Air Lines, Norwegian Cruise Line, Oncolytics Biotech, or Marathon Oil?
InvestorsObserver issues critical PriceWatch Alerts for TLRY, DAL, NCLH, ONCY, and MRO. 
From PR Newswire
Why Gastrointestinal (GI) Cancer Drugs Are Expected to See Significant Growth Over Next Few Years
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Why Gastrointestinal (GI) Cancer Drugs Are Expected to See Significant Growth Over Next Few Years
Financialnewsmedia.com News Commentary 
From PR Newswire
Oncolytics Biotech Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche’s Anti-PD-L1 Checkpoint Inhibitor
Tags ONCY News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced a new multi-indication gastrointestinal (GI) cancer study to be managed by AIO, a leading academic cooperative medical oncology group... 
From PR Newswire
Clinical Trials Delivering New Optimism in Fight Against Triple-Negative Breast Cancer
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Clinical Trials Delivering New Optimism in Fight Against Triple-Negative Breast Cancer
FN Media Group Presents USA News Group News Commentary 
From PR Newswire
Oncolytics Biotech® Appoints Richard Vile, Ph.D., to its Scientific Advisory Board
World-renowned scientist specializing in oncolytic viruses and immuno-oncology 
From PR Newswire
Thinking about buying stock in Canopy Growth Corp, Plantronics, Carparts.Com, Oncolytics Biotech, or Carnival Corp?
InvestorsObserver issues critical PriceWatch Alerts for CGC, PLT, PRTS, ONCY, and CCL. 
From PR Newswire
New Report Projects Immunotherapy Drug Market to Reach $274.6 Billion by 2025 with CAGR of 11.0%
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
New Report Projects Immunotherapy Drug Market to Reach $274.6 Billion by 2025 with CAGR of 11.0%
- FN Media Group Presents USA News Group News Commentary 
From PR Newswire
Oncolytics Biotech® to Participate in BIO Investor Forum Digital
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will be participating in the BIO Investor Forum Digital, which is taking place virtually from October 13-15, 2020. 
From PR Newswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.